Access
Reaching Those in Need
“Now is not the time to throttle back. Now is not the time to walk away from breakthroughs that are emerging. We are committed to getting this to finish line.”
We support the adoption, availability and affordability of new regimens for people with TB
In many high-burden countries, people most in need of better, faster-acting and affordable TB cures are often the most difficult to reach. To ensure any new and beneficial products have maximum impact on the TB pandemic, our "AAA Mandate" commits TB Alliance to ensuring that new TB drug treatments are adopted, available and affordable around the world.
Case study: Pediatric TB
Each year, 1 million children get sick with TB and about 210,000 die. Until recently, children have not had access to TB medicines in the proper doses or formulations. Care providers and parents have long had to crush or chop adult pills to approximate the correct dose. TB Alliance and its partners are solving this problem. In 2015, we introduced new TB cures for children in the correct doses and child-friendly forms, and are working to ensure they are widely available. By the end of 2017, an estimated 700,000 treatment courses of these new medicines were ordered by close to 80 countries.
